MediDrug Knowledge Base

The database contents are written by trained experts, mainly medical doctors, and approved by specialist doctors in pharmacology.

All clinical recommendations have been classified into four different categories according to the GRADE system ( using color-coding for the clinical classification.

The updates are regularly delivered four times per year.

The written consequence and recommendation texts have been kept short and concise.


SFINX is designed to aid every day clinical drug treatment. It is a drug-drug interaction database containing concise and validated information on the consequences of and the recommendations for more than 17.000 pairs. It produces warnings about potential drug interactions and offers medical recommendations on their avoidance and control.

SFINX contains information about relevant pharmacokinetic interactions, that can be supported by scientific literature or by clinical studies referred to in drug SPCs (Summary of the Product Characteristics), and furthermore some clinically important pharmacokinetic interactions, that can be foreseen on the basis of known metabolic pathways. Documented pharmacodynamic interactions are also included, unless they are apparent from the main pharmacological action of the substances, as with e.g. agonists/antagonists to the same receptor.

Interaction texts are based on substance names and, whenever relevant, substance formulations. They are classified according to clinical significance (A-D) and documentation level (0-4), which enables threshold settings for automated warnings. All contents of the database are developed in accordance with documented standard operating procedures.

Copyright of the database belongs to Medbase Ltd in Turku, Finland, the Karolinska Institute Department of Clinical Pharmacology in Stockholm, Sweden, and the Division of Drug Management and Informatics at Stockholm County Council, Sweden



PHARAO (PHARmacological Assessment On-line) is a database containing information on adverse drug effects. In PHARAO the adverse effect profile of more than 1300 drugs has been evaluated with regard to 9 clinically important adverse drug effects:
  • Anticholinergic effect
  • Risk of bleeding
  • Constipation
  • Orthostatism
  • QT-prolongation
  • Renal toxicity
  • Sedation
  • Risk of seizures
  • Serotonergic effect
With PHARAO, the users can check the adverse effect profile of a single drug e.g. before it is added to patients treatment, and perform a drug chart review to analyse the risk profile of patient's medication. Search results indicate the risk level for each adverse effect and points out the medications which are behind the risk.




RENBASE gives concise information in a user-friendly format, on the safety and dosage modifications of different drugs, in patients with renal failure. In addition to clinically used drugs, information exists also on vitamins, micronutrients and special license agents. The goal of Renbase is to provide up-to-date information on drug safety in renal failure, with a powerful search methods that enable quick help for decision making when prescribing or dispensing medications.

RENBASE analyses the pharmacokinetics and safety of various drugs and substances by dividing them into 4 categories, based on the degree of renal failure by glomerular filtration rate (GFR - according to the classification by the European Medicines Agency - EMEA - based on the serum creatinine concentration, age or sex (mild, moderate, severe, end-stage or dialysis).

The DOSAGE RECOMMENDATION is divided into four categories, using a color coding and allowing the user to be always aware of evidence based recommendations for dosage modification.

Information on the use and dosage recommandations during renal failure:
  • Includes special licence drugs
  • Vitamins and key micronutrients
A free text part, ADDITIONAL INFORMATION provides the user with a detailed, in some cases even indication specific, information on what is known about the pharmacokinetics and use of each drug during renal failure and in combination with various methods of dialysis as well as recommendations for clinical and laboratory monitoring when prescribing/dispensing a specific agent.

In RENBASE, the potential for NEPHROTOXICITY of each drug has been evaluated, which makes possible a listing and printing out such lists for patients.
The REFERENCES are PubMed-linked to enable a quick access to the original publications.



Gravbase / Lactbase

GRAVBASE-LACTBASE gives concise information on the safety of different drugs during pregnancy and lactation, in a user-friendly format. In addition to clinically used drugs, information are also available on vitamins, illicit substances of abuse and commonly used substances as caffeine, nicotine etc. The goal of Gravbase and Lactbase is to provide the user with an up-to-date information on the safety of various substances during pregnancy and lactation, with powerful search methods that enable quick help for decision making when prescribing or dispencing medications to women.

GRAVBASE-LACTBASE analyses the safety of various drugs and substances and divides them into 4 categories according to the level of documentation available and according to a risk analysis, made on the basis of the documentation. The databases produces short, clinically oriented, RECOMMENDATIONS, to enable a quick review of the safety information for clinicians /pharmacists.

GRAVBASE-LACTBASE also enables easy comparison of different substances within a therapeutic drug group, to ease the choice of most appropriate medication for various medical conditions during pregnancy and lactation.

Database provides data on gestational and locational exposures includes:
  • Over-the counter drugs and vitamins
  • Coffee, smoking and illicit drugs
  • Vaccines
  • Covers the modern drug therapy
The BACKGROUND part gives a concise review of the published and manufacturer and provides information on the safety of each substance during pregnancy and lactation in English.

The REFERENCES are PubMed-linked to enable a quick access to the original publications.